Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the consensus of $5.84 billion.
The life science giant reported adjusted earnings of $1.80 per share, beating the consensus of $1.64.
Non-GAAP core revenue increased 1.5% year over year, compared to the expectations of a growth in low single digits year over year.
Operating cash flow was $1.3 billion, and non-GAAP free cash flow was $1.1 billion.
Danaher’s second-quarter adjusted operating profit margin of 27.3% exceeded expectations of around 25.5%.
Also Read: Analyst Sees Opportunity In Danaher Stock As Sentiment Improves
Biotechnology sales increased to $1.85 billion compared to $1.71 billion a year ago, with core growth of 6%.
Sales in the Life Sciences segment remained flat at $1.78 billion, and diagnostic sales increased from $2.26 billion to $2.31 billion.
The company said, “DBS-driven execution, paired with another …